INSYS Therapeutics, Inc. (INSY) Can’t Be More Safe. Trades Significantly Higher

April 17, 2018 - By Winifred Garcia

Investors sentiment decreased to 0.76 in 2017 Q4. Its down 0.49, from 1.25 in 2017Q3. It dived, as 21 investors sold INSYS Therapeutics, Inc. shares while 29 reduced holdings. 20 funds opened positions while 18 raised stakes. 16.43 million shares or 9.75% less from 18.21 million shares in 2017Q3 were reported.
Parametric Limited Liability Co has invested 0% of its portfolio in INSYS Therapeutics, Inc. (NASDAQ:INSY). Sfmg Ltd Liability holds 11,994 shares. Voya Inv Mgmt Ltd Limited Liability Company reported 0% of its portfolio in INSYS Therapeutics, Inc. (NASDAQ:INSY). Dimensional Fund Advsr Lp holds 0% in INSYS Therapeutics, Inc. (NASDAQ:INSY) or 434,548 shares. 17,901 are held by State Board Of Administration Of Florida Retirement Sys. Federated Investors Pa stated it has 1,168 shares or 0% of all its holdings. Ubs Asset Mngmt Americas has 0% invested in INSYS Therapeutics, Inc. (NASDAQ:INSY). Korea-based Mirae Asset Glob Investments Comm has invested 0.19% in INSYS Therapeutics, Inc. (NASDAQ:INSY). 95,127 were reported by Shell Asset Management. Legal General Group Inc Pcl, a United Kingdom-based fund reported 9,348 shares. Us Bancorp De holds 0% or 75 shares in its portfolio. Manufacturers Life Insurance The holds 0% of its portfolio in INSYS Therapeutics, Inc. (NASDAQ:INSY) for 23,332 shares. Deutsche Bancshares Ag invested in 53,827 shares. Credit Suisse Ag invested in 0% or 81,928 shares. Panagora Asset Mgmt holds 0.01% or 212,791 shares in its portfolio.

The stock of INSYS Therapeutics, Inc. (NASDAQ:INSY) is a huge mover today! The stock increased 7.81% or $0.49 during the last trading session, reaching $6.76. About 991,955 shares traded or 29.33% up from the average. INSYS Therapeutics, Inc. (NASDAQ:INSY) has declined 45.03% since April 17, 2017 and is downtrending. It has underperformed by 56.58% the S&P500.
The move comes after 7 months positive chart setup for the $498.65M company. It was reported on Apr, 17 by Barchart.com. We have $7.30 PT which if reached, will make NASDAQ:INSY worth $39.89 million more.

INSYS Therapeutics, Inc. (NASDAQ:INSY) Ratings Coverage

Among 3 analysts covering Insys Therapeutics (NASDAQ:INSY), 2 have Buy rating, 1 Sell and 0 Hold. Therefore 67% are positive. Insys Therapeutics had 4 analyst reports since October 18, 2017 according to SRatingsIntel. On Wednesday, October 18 the stock rating was maintained by Jefferies with “Buy”. The rating was downgraded by PiperJaffray on Friday, March 9 to “Underweight”. The firm has “Buy” rating by RBC Capital Markets given on Friday, October 27. The firm has “Buy” rating by Jefferies given on Friday, November 3.

Insys Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes supportive care products. The company has market cap of $498.65 million. The firm markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant cancer patients in the United States. It currently has negative earnings. The Company’s lead product candidate is SYNDROS, an orally administered liquid formulation of dronabinol for treating CINV and anorexia associated with weight loss in patients with AIDS.

INSYS Therapeutics, Inc. (NASDAQ:INSY) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: